{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:10:11Z","timestamp":1761487811360},"reference-count":32,"publisher":"American Public Health Association","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Public Health"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:p> With the emergence of epidemic Neisseria meningitidis W135 meningitis in Burkina Faso during early 2002, the public health community was faced with the challenge of providing access to an appropriate and affordable vaccine in time for the upcoming 2003 epidemic season. <\/jats:p><jats:p> Recognizing the implications of the emergent threat, the World Health Organization developed a strategy, established a public\u2013private partnership to provide the needed vaccine, and then ensured that a stockpile was available for future use. <\/jats:p><jats:p> The trivalent N meningitidis ACW135 polysaccharide vaccine that resulted is now one of the primary tools for epidemic response in African meningitis belt countries. It will remain so for the foreseeable future and until appropriate and affordable conjugate vaccines become part of national immunization programs in the region. <\/jats:p>","DOI":"10.2105\/ajph.2005.075085","type":"journal-article","created":{"date-parts":[[2007,4,6]],"date-time":"2007-04-06T01:21:57Z","timestamp":1175822517000},"page":"S15-S22","source":"Crossref","is-referenced-by-count":7,"title":["Preparedness for Infectious Threats"],"prefix":"10.2105","volume":"97","author":[{"given":"Christopher B.","family":"Nelson","sequence":"first","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Birmingham","sequence":"additional","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Costa","sequence":"additional","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Daviaud","sequence":"additional","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Perea","sequence":"additional","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Paule","family":"Kieny","sequence":"additional","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tarantola","sequence":"additional","affiliation":[{"name":"At the time this work was completed, Christopher B. Nelson, Maureen Birmingham, Alejandro Costa, Joelle Daviaud, and Daniel Tarantola were with the Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. William Perea is with the Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva. Marie-Paule Kieny is with the Initiative for Vaccine Research, World Health Organization, Geneva."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"844","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"World Health Organization. Meningococcal disease serogroup W135. Wkly Epidemiol Rec. 2001;76:141\u2013142.","DOI":"10.1016\/S0140-6736(00)05293-4"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2005.apm1130305.x"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.3201\/eid0906.020565"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1080\/0036554021000026949"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.3.1083-1084.2002"},{"key":"R6","unstructured":"Lapeyssonie L. La m\u00e9ningite c\u00e9r\u00e9brospinale en Afrique. Bull World Health Organ. 1963;28(suppl):3\u2013114."},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(99)90106-2"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(02)90089-1"},{"key":"R11","unstructured":"World Health Organization. Meningococcal disease, serogroup W135, Burkina Faso Preliminary report. Wkly Epidemiol Rec. 2002;77:152\u2013156."},{"key":"R15","unstructured":"World Health Organization. Detecting Meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec. 2000;75: 306\u2013309."},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91533-1"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(86)90303-2"},{"key":"R18","unstructured":"Odugbemi T, Ademidun O, Agbabiaka A, Banjo T. Nasopharyngeal carriage of Neisseria meningitidis among school children at Ijede, Lagos State, Nigeria. Ethiop Med J. 1992;30: 33\u201336."},{"key":"R19","unstructured":"World Health Organization. Neisseria meningitidis strains identified in Africa. Wkly Epidemiol Rec. 1993;68: 311\u2013312."},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880005233X"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.1998.00300.x"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.3201\/eid0803.010308"},{"key":"R23","unstructured":"Fourn L, Makoutode M, Ouendo M, and Tounkara B. Meningococcal meningitis epidemics in Benin [in French]. Sante. 2004;14:153\u2013159."},{"key":"R24","unstructured":"World Health Organization. Health conditions for travelers to Saudi Arabia for the pilgrimage to Mecca (Hajj). Wkly Epidemiol Rec. 2005;80: 431\u2013432."},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08416-7"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.142-164.2006"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00455-3"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16034-0"},{"key":"R35","unstructured":"World Health Organization. Detecting Meningococcal meningitis epidemics in highly-endemic African countries: WHO recommendation. Wkly Epidemiol Rec 2000;75:306\u2013309."},{"key":"R37","unstructured":"Yergeau A, Alain L, Pless R, Robert Y. Adverse events temporally associated with meningococcal vaccines. Can Med Assoc J. 1996;154:503\u2013507."},{"key":"R38","unstructured":"US Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1\u201310."},{"key":"R41","unstructured":"Chandramohan D, Coleman P, Nelson CB et al. Review of immunogenicity endpoints for the evaluation of meningococcal vaccines in affected populations. Vaccine. In press."},{"key":"R42","unstructured":"Aseffa A, Bedru A, Yamuah L, et al. Immunogenicity of Mencevax ACW135 vaccine among young children. Vaccine. In press."},{"key":"R45","unstructured":"Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ. 2001;79:735\u2013741."},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09096-7"},{"key":"R47","unstructured":"Widdus R. Public-private partnerships for health: their main targets, their diversity, and their future directions. Bull World Health Organ. 2001;79: 713\u2013720."},{"key":"R49","unstructured":"Towse A, Kettler H. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bull World Health Organ. 2005;83: 301\u2013307."}],"container-title":["American Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ajph.aphapublications.org\/doi\/pdf\/10.2105\/AJPH.2005.075085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T23:01:47Z","timestamp":1652137307000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajph.aphapublications.org\/doi\/full\/10.2105\/AJPH.2005.075085"}},"subtitle":["Public\u2013Private Partnership to Develop an Affordable Vaccine for an Emergent Threat: The Trivalent <i>Neisseria meningitidis<\/i> ACW135 Polysaccharide Vaccine"],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":32,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.2105\/AJPH.2005.075085"],"URL":"https:\/\/doi.org\/10.2105\/ajph.2005.075085","relation":{},"ISSN":["0090-0036","1541-0048"],"issn-type":[{"value":"0090-0036","type":"print"},{"value":"1541-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}